{
    "title": "112_hr2245",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Preserving Access to Life-Saving \nMedications Act of 2011''.\n\nSEC. 2. DISCONTINUANCE OR INTERRUPTION OF THE MANUFACTURE OF A \n              PRESCRIPTION DRUG.\n\n    (a) In General.--Section 506C of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 356c) is amended to read as follows:\n\n``SEC. 506C. DISCONTINUANCE OR INTERRUPTION OF THE MANUFACTURE OF A \n              PRESCRIPTION DRUG.\n\n    ``(a) Definitions.--In this section:\n            ``(1) The term `average historic demand' means the \n        individual manufacturer's average monthly volume of sales of \n        the drug during the last calendar year.\n            ``(2) The term `discontinuance' means the permanent \n        termination of the manufacture of a drug by an individual \n        manufacturer.\n            ``(3) The term `interruption' means a change that--\n                    ``(A) may result in the total supply of a drug \n                manufactured by the individual manufacturer not meeting \n                average historic demand; and\n                    ``(B) consists of--\n                            ``(i) a change in the supply of one or more \n                        raw materials, including active pharmaceutical \n                        ingredients;\n                            ``(ii) an unplanned interruption in ability \n                        to produce the drug;\n                            ``(iii) a business decision affecting the \n                        manufacture of the drug, such as a merger or a \n                        change in production output; or\n                            ``(iv) any other type change that could \n                        have the result described in subparagraph (A), \n                        as determined by the Secretary.\n    ``(b) Notifications by Manufacturers.--\n            ``(1) In general.--A manufacturer of a drug that is subject \n        to section 503(b)(1) and marketed in interstate commerce shall \n        notify the Secretary of a discontinuance or interruption in the \n        manufacture of such drug.\n            ``(2) Notification period.--A notification pursuant to \n        paragraph (1) shall be submitted to the Secretary--\n                    ``(A) in the case of a planned discontinuance, at \n                least 6 months prior to the date of such \n                discontinuance; and\n                    ``(B) in the case of any other discontinuance or \n                interruption--\n                            ``(i) at least 6 months prior to the date \n                        of such discontinuance or interruption; or\n                            ``(ii) if the manufacturer cannot provide 6 \n                        months advance notice, as soon as practicable \n                        after the manufacturer--\n                                    ``(I) becomes aware of such \n                                discontinuance; or\n                                    ``(II) becomes aware that such \n                                interruption may result in the total \n                                supply of the drug manufactured by the \n                                individual manufacturer not meeting \n                                average historic demand.\n            ``(3) Additional information.--A manufacturer may, but is \n        not required to, include in a notification submitted pursuant \n        to paragraph (1) information about an alternative source of the \n        drug or the availability of a drug with the same active \n        ingredient.\n            ``(4) Reduction in notification period.--The notification \n        period required under paragraph (2) for a manufacturer may be \n        reduced if the manufacturer certifies to the Secretary that \n        good cause exists for the reduction, such as a situation in \n        which--\n                    ``(A) a public health problem may result from \n                continuation of the manufacturing for the 6-month \n                period;\n                    ``(B) a biomaterials shortage prevents the \n                continuation of the manufacturing for the 6-month \n                period;\n                    ``(C) a liability problem may exist for the \n                manufacturer if the manufacturing is continued for the \n                6-month period;\n                    ``(D) continuation of the manufacturing for the 6-\n                month period may cause substantial economic hardship \n                for the manufacturer;\n                    ``(E) the manufacturer has filed for bankruptcy \n                under chapter 7 or 11 of title 11, United States Code; \n                or\n                    ``(F) the manufacturer can continue the \n                distribution of the drug involved for 6 months.\n            ``(5) Other reductions in notification period.--The \n        Secretary may reduce the notification period required under \n        paragraph (2) based on--\n                    ``(A) the type of discontinuance or interruption at \n                issue; and\n                    ``(B) any other factor, as determined by the \n                Secretary.\n            ``(6) Confidentiality of information.--Any information \n        provided to the Secretary under paragraph (1) shall be treated \n        as trade secret or confidential information subject to section \n        552(b)(4) of title 5 and section 1905 of title 18.\n            ``(7) Enforcement.--\n                    ``(A) Any manufacturer that knowingly fails to \n                submit a notification in violation of paragraph (1) \n                shall be subject to a civil money penalty not to exceed \n                $10,000 for each day on which the violation continues, \n                and not to exceed $1,800,000 for all such violations \n                adjudicated in a single proceeding.\n                    ``(B) Not later than 180 days after the date of the \n                enactment of the Preserving Access to Life-Saving \n                Medications Act of 2011, the Secretary shall, subject \n                to subparagraph (A), promulgate final regulations \n                establishing a schedule of civil monetary penalties for \n                violations of paragraph (1).\n                    ``(C) The provisions of paragraphs (5), (6), and \n                (7) of section 303(f) shall apply with respect to a \n                civil penalty under this paragraph to the same extent \n                and in the same manner as such provisions apply with \n                respect to a civil penalty under paragraph (1), (2), \n                (3), (4), or (9) of section 303(f).\n    ``(c) Notifications by Secretary.--\n            ``(1) Drug shortage defined.--In this section, the term \n        `drug shortage' means, with respect to a drug, a period of time \n        when the total supply of such drug available at the user level \n        will not meet the demand for such drug at the user level as \n        determined by the Secretary.\n            ``(2) Public notification.--\n                    ``(A) In general.--Subject to subsection (b)(6), \n                the Secretary shall--\n                            ``(i) publish on the public Internet Web \n                        site of the Food and Drug Administration \n                        information on--\n                                    ``(I) the types of discontinuances \n                                and interruptions for which a \n                                notification is required under \n                                subsection (b)(1); and\n                                    ``(II) actual drug shortages; and\n                            ``(ii) to the maximum extent practicable, \n                        distribute such information to appropriate \n                        health care providers and patient \n                        organizations.\n                    ``(B) Duration.--The Secretary shall include in any \n                publication or distribution under subparagraph (A), \n                when possible, an estimate of the expected duration of \n                any discontinuance or interruption or actual drug \n                shortage.\n            ``(3) Identification and notification of drugs vulnerable \n        to drug shortage.--\n                    ``(A) In general.--If the Secretary determines \n                using the criteria under subparagraph (B) that a drug \n                may be vulnerable to a drug shortage, the Secretary \n                shall notify the manufacturer of the drug of--\n                            ``(i) such determination; and\n                            ``(ii) the Secretary's duty to collaborate \n                        to improve continuity of supply plans under \n                        paragraph (4).\n                    ``(B) Evidence-based criteria.--The Secretary shall \n                implement evidence-based criteria for identifying drugs \n                that may be vulnerable to a drug shortage. Such \n                criteria shall be based on--\n                            ``(i) the number of manufacturers of the \n                        drug;\n                            ``(ii) the sources of raw material or \n                        active pharmaceutical ingredients;\n                            ``(iii) the supply chain characteristics, \n                        such as production complexities; and\n                            ``(iv) the availability of therapeutic \n                        alternatives.\n            ``(4) Continuity of supply plans.--\n                    ``(A) In general.--With respect to drugs that are \n                vulnerable to a drug shortage (as determined under \n                paragraph (3)), the Secretary shall collaborate with \n                manufacturers and other stakeholders (such as \n                distributors and health care providers) to establish \n                and improve continuity of supply plans, so that such \n                plans include a process for addressing drug shortages.\n                    ``(B) Limitation on secretary's authority.--The \n                Secretary may not in any case require a manufacturer--\n                            ``(i) to manufacture a drug in the event of \n                        a discontinuance or interruption; or\n                            ``(ii) to delay or alter a discontinuance \n                        or interruption.\n                    ``(C) Allocation by manufacturer.--No provision of \n                Federal law shall be construed to prohibit a \n                manufacturer from, or penalize a manufacturer for, \n                allocating distribution of its products in order to \n                manage an actual or potential drug shortage.\n    ``(d) Rulemaking.--The Secretary shall carry out this section \npursuant to regulations promulgated after providing notice and an \nopportunity for comment.''.\n    (b) Applicability; Transitional Period.--Section 506C of the \nFederal Food, Drug, and Cosmetic Act, as amended by subsection (a), \napplies with respect to discontinuances, interruptions, and drug \nshortages (as such terms are used in such section 506C) that occur on \nor after the day that is 1 year after the date of the enactment of this \nAct. Until such day, the provisions of section 506C of the Federal \nFood, Drug, and Cosmetic Act, as in effect on the day before the \nenactment of this Act, shall continue to apply.\n\nSEC. 3. REPORTS TO CONGRESS.\n\n    The Secretary of Health and Human Services shall submit to the \nCongress--\n            (1) not later than the date that is 1 year after the date \n        of the enactment of this Act, a report describing the actions \n        taken by the Secretary during the previous 1-year period to \n        address drug shortages (as defined in section 506C of the \n        Federal Food, Drug, and Cosmetic Act, as amended by section 2) \n        through all aspects of the prescription drug supply chain; and\n            (2) every 5 years thereafter, a report describing such \n        actions taken by the Secretary during the previous 5-year \n        period.\n\nSEC. 4. GAO STUDY.\n\n    (a) Study.--The Comptroller General of the United States shall \nconduct a study--\n            (1) to examine how the Food and Drug Administration \n        identifies and responds to drug shortages (as defined in \n        section 506C of the Federal Food, Drug, and Cosmetic Act, as \n        amended by section 2);\n            (2) to examine the possible causes of such drug shortages, \n        including manufacturing problems, breakdown in the supply chain \n        delivery system, changes in the supply of raw materials, \n        stockpiling at the wholesale or provider level, and restrictive \n        regulatory requirements;\n            (3) to identify if there is adequate communication between \n        industry, the Food and Drug Administration, distributors, and \n        end users;\n            (4) to analyze the effects of the enactment of this Act on \n        the ability of the Food and Drug Administration to identify and \n        ameliorate such drug shortages; and\n            (5) to identify any additional measures that need to be \n        taken to prevent or address such drug shortages.\n    (b) Report.--Not later than 1 year after the date of the enactment \nof this Act, the Comptroller General shall submit a report to the \nCongress on the results of the study under subsection (a)."
}